https://orcid.org/0000-0002-2181-085X
References
- Azevedo O , CordeiroF, GagoMFet al. Fabry disease and the heart: a comprehensive review. Int. J. Mol. Sci., 22(9), 1–36 (2021).
- Lenders M , NordbeckP, KurschatCet al. Treatment of Fabry disease management with migalastat - outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur. Heart J. Cardiovasc. Pharmacother., 8(3), 272–281 (2022).
- Azevedo O , GagoMF, Miltenberger-MiltenyiG, SousaN, CunhaD. Fabry disease therapy: state-of-the-art and current challenges. Int. J. Mol. Sci., 22(1), 1–16 (2021).
- Oommen S , ZhouY, MeiyappanM, GurevichA, QiuY. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants. Mol. Genet. Metab., 127(1), 74–85 (2019).
- The Human Gene Mutation Database . http://www.hgmd.cf.ac.uk/ac/gene.php?gene=gla
- Germain DP , NichollsK, GiuglianiRet al. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the Phase III randomized, multicenter, double-blind clinical trial and extension study. Genet. Med., 21(9), 1987–1997 (2019).
- Nowak A , Huynh-DoU, KrayenbuehlPA, BeuschleinF, SchiffmannR, BarbeyF. Fabry disease genotype, phenotype, and migalastat amenability: insights from a national cohort. J. Inherit. Metab. Dis., 43(2), 326–333 (2020).
- European Medicines Agency . Galafold - summary of product characteristics. 1–29 (2010). https://www.ema.europa.eu/en/medicines/human/EPAR/galafold
- Lenders M , StappersF, BrandE. In vitro and in vivo amenability to migalastat in Fabry disease. Mol. Ther. Methods Clin. Dev., 19, 24–34 (2020).
- McCafferty EH , ScottLJ. Migalastat: a review in Fabry disease. Drugs, 79(5), 543–554 (2019).
- Benjamin ER , DellaValle MC, WuX et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Gene. Med., 19(4), 430–438 (2017).
- Germain DP , HughesDA, NichollsKet al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med., 375(6), 545–555 (2016).
- Hughes DA , NichollsK, ShankarSPet al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised Phase III ATTRACT study. J. Med. Genet., 54(4), 288–296 (2017).
- Carvalho Silva DM , MarquesN, AzevedoOet al. P.G360R is a pathogenic GLA gene mutation responsible for a classic phenotype of Fabry disease. Cardiology, 144(3–4), 125–130 (2019).
- Amicus Therapeutics data on file . Galafold® (migalastat): individual mutant form summary of results.
- National Center for Biotechnology Information . http://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000222135.12
- Liao HC , HsuTR, YoungLet al. Functional and biological studies of α-galactosidase A variants with uncertain significance from newborn screening in Taiwan. Mol. Genet. Metab., 123(2), 140–147 (2018).
- Braberg H , MoehleEA, ShalesM, GuthrieC, KroganNJ. Genetic interaction analysis of point mutations enables interrogation of gene function at a residue-level resolution: exploring the applications of high-resolution genetic interaction mapping of point mutations. BioEssays, 36(7), 706–713 (2014).